Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe University of Hong Kong
About this trial
To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Disqualifiers
participant who is unable to give informed consent in a prospective cohort.
Trial population
Adult patients aged 18 years or older who are undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Queen Mary Hospital.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupGroup A: All patients receiving allogeneic HSCT at Queen Mary Hospital, Hong Kong
Trial outcomes
Primary outcomes
1
Overall survival
Time from HSCT to death or latest follow-up
Time frame
5 year2
Relapse-free survival
Time from HSCT to relapse, death or latest follow-up
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov